Business
Pharvaris to Present Clinical Data at the EAACI Annual Congress 2026
Pharvaris to Present Clinical Data at the EAACI Annual Congress 2026
About this update from Pharvaris N.v.
ZUG, Switzerland, May 29, 2026 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet needs of those living with bradykinin-mediated diseases such as hereditary angioedema (HAE) and acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH), today announced the acceptance of one abstract for oral presentation and seven abstracts for flash talk/poster presentation at the European Academy of Allergy and Clinical Immunology (EAACI) Annual Congress 2026, to be held from June 12-15, 2026, in Istanbul, Turkey. Details of the presentations are as follows: Title: Oral Deucrictibant Immediate-Release Capsule for On-Demand Treatment of Hereditary Angioedema Attacks: End of Progression Results in the Phase 3 RAPIDe-3 TrialPresenter: Mauro Cancian, M.D., Ph.D.Format: Oral Presentation Date, time: Friday, June 12, 2026, 3:00-4:30 p.m. TRT (8:00-9:30 a.m. EDT) Title: Clinical Cardiovascular Safety Assessment of Oral DeucrictibantPresenter: Anne Lesage, Ph.D.Format: Poster Presentation Date, time: Friday, June 12, 2026, 12:00-1:00 p.m. TRT (5:00-6:00 a.m. EDT) Title: A Clinically Validated Kinin Biomarker Assay to Differentiate Bradykinin-Mediated from Mast Cell-Mediated AngioedemaPresenter: Evangelia Pardali, Ph.D. Format: Poster PresentationDate, time: Friday, June 12, 2026, 12:00-1:00 p.m. TRT (5:00-6:00 a.m. EDT) Title: Evaluations of Safety Margins and Response to Deucrictibant Extended-Release (XR) Tablet in Combination with Deucrictibant Immediate-Release (IR) CapsulePresenter: Anne Lesage, Ph.D.Format: Poster Presentation Date, time: Saturday, June 13, 2026, 12:00-1:00 p.m. TRT (5:00-6:00 a.m. EDT) Title: Oral Deucrictibant Immediate-Release Capsule for On-Demand Treatment of Hereditary Angioedema Attacks: Results of the Phase 3 RAPIDe-3 TrialPresenter: Philip Li, M.D., FRCPFormat: Poster Presentation Date, time: Saturday, June 13, 2026, 12:00-1:00 p.m. TRT (5:00-6:00 a.m. EDT) Title: RAPIDe-3 Patient Voices: Qualitative Insights from the Phase 3 Study of Oral Deucrictibant for On-Demand Treatment of Hereditary Angioedema AttacksPresenter: Anna Valerieva, M.D., Ph.D.Format: Poster PresentationDate, time: Saturday, June 13, 2026, 12:00-1:00 p.m. TRT (5:00-6:00 a.m. EDT) Title: Results of the Phase 2 CHAPTER-1 Open-Label Extension Study on the Long-Ter...